deferasirox has been researched along with Liver Dysfunction in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abbaszadeh, H; Mottaghi, S | 1 |
| Coates, TD; Giardina, P; Glynos, T; Harmatz, P; Kang, BP; Paley, C; Thompson, A; Wood, JC | 1 |
| Brissot, P; Deugnier, Y; Loréal, O | 1 |
1 review(s) available for deferasirox and Liver Dysfunction
| Article | Year |
|---|---|
Iron and the liver: update 2008.
Topics: Antimicrobial Cationic Peptides; Benzoates; Deferasirox; Hemochromatosis; Hepcidins; Homeostasis; Humans; Iron; Iron Chelating Agents; Liver; Liver Diseases; Triazoles | 2008 |
2 trial(s) available for deferasirox and Liver Dysfunction
| Article | Year |
|---|---|
Grape seed extract in combination with deferasirox ameliorates iron overload, oxidative stress, inflammation, and liver dysfunction in beta thalassemia children.
Topics: beta-Thalassemia; C-Reactive Protein; Child; Deferasirox; Ferritins; Grape Seed Extract; Humans; Inflammation; Iron; Iron Overload; Liver Diseases; Oxidative Stress; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2023 |
Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial.
Topics: Benzoates; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferasirox; Ferritins; Follow-Up Studies; Humans; Iron Chelating Agents; Liver Diseases; Siderosis; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles | 2010 |